



Assessment Framework In Israel

WCBP January 2018, Dr. Vered Ben Naim

Applications

“Regular” pathway
Accelerated pathway

Requirements

Full Dossier
CPP
FDA/EMA assessment reports
Questions & Answers

Regulation

Pharmacist’ Directive & Regulations
IMOH guidelines
ICH & EMA guidelines adoption
FDA & WHO guidelines
EP/ USP/ JP

Making a Decision

Full Assessment
Advisory Committee
Risk-Balance approach



Current Regulation Framework- Advance Therapies

Legislation

Definition of a Medicinal Product
Cell and Tissues supervision and enforcement

Hospital Exemption- EU model

In hospitals
Under physician's responsibility
Justification for CL exclusion
Under GMP, Unique Quality standards
Tractability

GMP

EC Directives & guideline
Flexibility
Risk-based approach
Case by case

Clinical trials & Licensing

IMOH guidelines
Classification
EMA guidelines
Ad-hoc advisory committee